MDT Medtronic Plc

$MDT I got in huge yesterday on Boston, BSX that fell from $98 to $43 . Boston is going to get bought out after 50% off as it is also a great company. Watch and learn .

$MDT - TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study

$MDT 🏥 Medtronic plc received FDA approval for a U.S. labeling update to its Symplicity Spyral renal denervation system based on SPYRAL AFFIRM post-approval study results showing significant six-month blood pressure reductions. Curated for market relevance

$MDT | BULLISH 🐂 ⭐ Setup Quality Grade: B+ 📌 Grade Justification: • Profitability: Top 15th Percentile ($37.5B TTM revenue, $5.3B net income, 65.0% gross margin, 3.27% dividend yield). • Revenue Growth: Top 30th Percentile (+9.9% reported / +6.6% organic Q4 sales growth; $5.40–$5.50 FY27 EPS guide). • Options Flow: Short-Term Call Sweeps ($88.4K sweep on Oct 16 $90C + $30.3K sweep on Oct 16 $90C at the ask). • Technical Setup: B+ Grad (1W ascending channel holding $88.00–$89.50 spot above primary volume profile shelf). 🏢 Profile: World’s largest standalone medical device titan ($112B+ market cap) advancing cardiovascular, surgical, and neuroscience tech 📉 Setup: 1W ascending channel support holding $88.00–$89.50 spot directly on volume shelf support! 🔎 Options Flow: Oct 16 $90C (1.8% OTM) ($88.4K sweep at ask) 💸. 🎯 Levels: • Bulls: Hold $87.50 & claim $92.00 ➡️ Targets: $95.50 / $102.00 / $112.00+ 🚀 • Bears: Break under $85.00 support. 🛑 #hovdid

$MDT An Institution just bought oct 16 130c/p Straddle @ $42.50 ea (35,000 contracts). breakeven $87.5 Damn!

$MDT Barclays analyst Christopher Pasquale initiates coverage on Medtronic with a Equal-Weight rating and announces Price Target of $95.

$MDT Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation

$MDT The medical device sector has not been getting enough attention among Abbott, Boston Scientific, Medtronic and Johnson Johnson. As money rolled out of the AI chip sector, you want to get in the medical device valued stocks now.

$MDT - Medtronics. Breaking out of cup with handle on the weekly. Price target 112$. Remember that the earnings are 24th of November.

$MDT Medtronic beat expectations and raised its FY27 guide to 7.25-7.75% organic growth and 5.94-6.00 non-GAAP EPS. Growth was led by Cardiovascular, up 19% with cardiac ablation taking share, and by Neuroscience and Surgical. With the MiniMed diabetes business being separated, the remaining company grows faster. At about 16x FY27 EPS, the stock is still valued like the low-growth Medtronic of the past vs. a sustained step up in organic growth, which deserves a higher multiple.

$MDT — Medtronic's recent analyses covered strong revenue and earnings growth, alongside strategic advancements in robotics and spin-offs. Recent analyses of Medtronic plc (MDT) examined its financial performance, noting significant year-over-year increases in revenue and net income. The reports also tracked strategic initiatives including investments in robotics and the spin-off of its MiniMed division, alongside market technical indicators. On the upside: Year-over-year revenue growth of 13.7%. Year-over-year net income growth of 40.7%. Positive short-term upward momentum indicated by 10-day EMA. Strong buying pressure indicated by MFI above 70. On the risk side: Stock price trading below 50-day and 200-day SMAs in the prior week. RSI falling below 50, indicating a lack of strong buying pressure in the prior week. MACD below zero, indicating bearish momentum in the prior week. Stock price trading closer to the lower Bollinger Band in the prior week.

🟢 $MDT 90C Dec 18 💰 $105,000 premium 💵 $5.8/contract 📊 2.7x Vol/OI 📍 Spot $91.99 💰 Large premium | 🚨 Repeat sweep 🌊 Dark Flow | Options Flow

$MDT why all the sudden MDT is too attractive? Is today deciding the shares between mdt and minimed?

$MDT — Medtronic's strategic advancements, including platform development and a significant spin-off, were central to recent analyses, alongside technical indicators suggesting a bearish trend. Upside noted: Year-over-year quarterly revenue growth was 13.7%. Year-over-year quarterly earnings growth was 40.7%. Dividend yield of 3.28%. Current ratio of 2.067. Risk noted: Current price is below both the 50-day SMA and the 200-day SMA. RSI is below the neutral 50 level. MACD is below zero, indicating bearish momentum. Recent analyses examined Medtronic's strategic initiatives, including the advancement of its Altaviva and Symplicity Spyral platforms and the spin-off of its MiniMed division. The company's significant investment in robotics and its commitment to serving a large patient base were also noted. Technical indicators, such as SMAs and RSI, suggested a bearish short-to-medium term trend, despite some short-term upward momentum.

$MDT MMED will get put out of business by CRSP. Crisper technology will provide a cure. No wonder MDT is spinning it out.

$MDT $87.09 | Mixed / Sideways RSI 40.5 (Bearish) MACD Bearish | Vol 2.9x MA20 $89.96 | MA50 $90.07 MA200 $88.54 S $78.97 | R $95.41 Cap $111.40B P/E 21.4 | Fwd 13.6 Moderate Outlook | $84.39 (-3.1%)